- Home
- BRC vs MRUS Comparison
BRC vs MRUS Comparison
Compare BRC & MRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRC
- MRUS
- Stock Information
- Founded
- BRC 1914
- MRUS 2003
- Country
- BRC United States
- MRUS Netherlands
- Employees
- BRC N/A
- MRUS N/A
- Industry
- BRC Miscellaneous manufacturing industries
- MRUS Biotechnology: Pharmaceutical Preparations
- Sector
- BRC Consumer Discretionary
- MRUS Health Care
- Exchange
- BRC Nasdaq
- MRUS Nasdaq
- Market Cap
- BRC 3.4B
- MRUS 2.7B
- IPO Year
- BRC 1984
- MRUS 2016
- Fundamental
- Price
- BRC $69.82
- MRUS $56.07
- Analyst Decision
- BRC
- MRUS Strong Buy
- Analyst Count
- BRC 0
- MRUS 15
- Target Price
- BRC N/A
- MRUS $88.87
- AVG Volume (30 Days)
- BRC 198.9K
- MRUS 1.6M
- Earning Date
- BRC 05-16-2025
- MRUS 05-07-2025
- Dividend Yield
- BRC 1.38%
- MRUS N/A
- EPS Growth
- BRC 3.35
- MRUS N/A
- EPS
- BRC 4.03
- MRUS N/A
- Revenue
- BRC $1,459,732,000.00
- MRUS $54,732,000.00
- Revenue This Year
- BRC $13.46
- MRUS $39.00
- Revenue Next Year
- BRC $4.07
- MRUS $7.48
- P/E Ratio
- BRC $17.31
- MRUS N/A
- Revenue Growth
- BRC 8.62
- MRUS 42.77
- 52 Week Low
- BRC $62.70
- MRUS $33.19
- 52 Week High
- BRC $77.68
- MRUS $61.28
- Technical
- Relative Strength Index (RSI)
- BRC 45.58
- MRUS 66.86
- Support Level
- BRC $69.26
- MRUS $49.46
- Resistance Level
- BRC $71.28
- MRUS $56.74
- Average True Range (ATR)
- BRC 1.63
- MRUS 3.37
- MACD
- BRC -0.41
- MRUS 1.57
- Stochastic Oscillator
- BRC 15.73
- MRUS 91.31
About BRC Brady Corporation
Brady Corp provides identification solutions and workplace safety products. The company offers identification and healthcare products that are sold under the Brady brand to maintenance, repair, and operations as well as original equipment manufacturing customers. Products include safety signs and labeling systems, material identification systems, wire identification, patient identification, and people identification. Brady also provides workplace safety and compliance products such as safety and compliance signs, asset tracking labels, and first-aid products. The company is organized and managed on a geographic basis with two reportable segments: Americas & Asia which derives maximum revenue, and Europe & Australia.
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.